NCT02499328
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Serine/Threonine Kinase Inhibitor, Tyrosine Kinase Inhibitor, Misc Inhibitor, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with clinically active brain metastases
https://ClinicalTrials.gov/show/NCT02499328